Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Samrat Pharmachem's annualized net income for the quarter that ended in Mar. 2026 was ₹-81 Mil. Samrat Pharmachem's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹682 Mil. Therefore, Samrat Pharmachem's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -11.95%.
The historical rank and industry rank for Samrat Pharmachem's Return-on-Tangible-Equity or its related term are showing as below:
BOM:530125'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4.73 Med: 15.63 Max: 44.96
Current: -4.72
During the past 13 years, Samrat Pharmachem's highest Return-on-Tangible-Equity was 44.96%. The lowest was -4.73%. And the median was 15.63%.
BOM:530125's Return-on-Tangible-Equity is ranked worse than 81.94% of 1567
companies
in the Chemicals industry
Industry Median: 5.82
vs BOM:530125: -4.72
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Samrat Pharmachem Return-on-Tangible-Equity Related Terms
Samrat Pharmachem Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530125 vs DOW: Return-on-Tangible-Equity Comparison
For the Chemicals subindustry, Samrat Pharmachem's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem Return-on-Tangible-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -11.95% mean?
Samrat Pharmachem (BOM:530125) has a Return-on-Tangible-Equity of -11.95% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Samrat Pharmachem and its competitors. According to the industry distribution chart, Samrat Pharmachem ranks #1284 out of 1567 companies in the Chemicals industry, placing it in the top 81.9%.
Is Samrat Pharmachem's Return-on-Tangible-Equity too high?
Samrat Pharmachem's current Return-on-Tangible-Equity is -11.95%. Based on the distribution chart, Samrat Pharmachem ranks #1284 out of 1567 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Return-on-Tangible-Equity compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #1284 out of 1567 companies for Return-on-Tangible-Equity. This places Samrat Pharmachem in the lower half of its industry. The industry median Return-on-Tangible-Equity is 5.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Chemicals company?
The median Return-on-Tangible-Equity among Chemicals companies is 5.82, based on 1,567 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median Return-on-Tangible-Equity is 5.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current Return-on-Tangible-Equity is -11.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.74, compared to a current price of ₹243.55 — trading 32.9% below its estimated fair value. The current Return-on-Tangible-Equity is -11.95%. Samrat Pharmachem's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Return-on-Tangible-Equity is -11.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹243.55 is trading 32.9% below its estimated GF Value™ of ₹362.74.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
Return-on-Tangible-Equity: -11.95%
GF Value™: ₹362.74 vs. price of ₹243.55 (32.9% below fair value)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
63GF Score
Get the complete analysis for BOM:530125
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
